A validation study of a lupus anticoagulant testing algorithm, undertaken by Ghent University Hospital in Belgium and presented at a recent symposium, points to increased quality through standardisation and harmonisation.
Antiphospholipid syndrome (APS) and HIV/AIDS were officially identified in the early 1980s and have been described as the two new life-threatening diseases of the late 20th century. Now, over 30 years later, everyone has heard about the fight against HIV/AIDs and how one simple test of blood, and now saliva, can detect the virus.
The same cannot be said for the complex autoimmune disorder, originally known as Hughes syndrome, or sticky blood, now more usually defined as APS. The significance of the condition is still not widely understood outside specialist haematologists and laboratory staff, and remains a difficult condition to detect.
The Stago Group is recognised internationally for its scientific excellence in the field of coagulation and haemostasis, with a global commitment to aiding disease management. To add to its long-established portfolio of reagents, Stago unveiled a major initiative on standardisation and interpretation of lupus anticoagulant (LA) testing at its recent UK Scientific Symposium.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.